IMRA (near 52-week low with potential to gap fill)

Took a massive dip upon failing FDA approval but still a solid company. Dipped to about 13.7 as of 01/25/2021 and looking for it to fill the gap at around 15. Could potentially make a steady climb and pop if FDA approval does succeed once again.

back

IMRA (near 52-week low with potential to gap fill)

bullish

Took a massive dip upon failing FDA approval but still a solid company. Dipped to about 13.7 as of 01/25/2021 and looking for it to fill the gap at around 15. Could potentially make a steady climb and pop if FDA approval does succeed once again.

Comments

Write your comment....

Sign in to comment

read-time
< 1 min

15.13

Target Price

7/ 10

Confidence

2-4 Weeks

Timeframe
Share
catalyst icon
Earnings Release
catalyst icon
News
catalyst icon
SEC Filing
catalyst icon
Sentiment
catalyst icon
Other Catalyst

IMRA Channel

Start new chat
aiodd-ad
next